An analysis of FDA side-effects reports by healthcare informatics firm AdverseEvents has uncovered potentially worrisome signals for two of Novartis’ meds, Exelon for Parkinson’s and Alzheimer’s disease, and Stalevo for Parkinson’s disease. AdverseEvents reported 11 cases of cardiopulmonary failure, 5 cases of acute respiratory failure and almost 1,200 deaths in Exelon patients. The research also linked Stalevo to 8 cases of stroke. Via FiercePharma. Posted April 7, 2015.
AdverseEvents: Analysis of side-effect reports turns up troubling safety signals for Novartis, Eisai drugs
Alanna McCatty
Alanna McCatty is founder and CEO of McCatty Scholars, an organization that devises and implements financial literacy programs for students to combat the nationwide issue of the loss of educational opportunity due to the ramifications of burdensome student debt. At MedShadow, she reports on new findings and research on the side effects of prescription drugs. She is a graduate of Pace University.
Advertisement
